- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05180136
Efficacy of Rice Bran Extract in Mildly to Moderately Depressed Adults
January 31, 2024 updated by: Sang Yeoup Lee, Pusan National University Yangsan Hospital
Efficacy and Tolerability of Rice Bran Extract in Mildly to Moderately Depressed Patients: a Double-blind, Randomized, Placebo-controlled Study
The investigators conduct a randomized, double-blind, placebo-controlled study to investigate the effects and tolerability of rice bran extract on depressive symptoms and related biomarkers in mildly to moderately depressed patients for 8 weeks.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
A previous animal study has indicated that rice bran extract provided inhibition of MAO-B enzyme activity and ROS formation in a corticosterone-induced depression-like animal model.
Therefore, the investigators conduct a randomized, double-blind, placebo-controlled study to investigate the effects of rice bran extract on depressive symptoms and related biomarkers in mildly to moderately depressed patients for 8 weeks; the safety of the compound is also evaluated.
The Investigators examine the Korean version of the Hamilton Depression Rating Scale, the Korean Version of the Beck-II Depression Inventory, the Korean version of the Patient Health Questionnaire-9, the Perceived Stress Scale, the Korean version of the Beck Anxiety Inventory and biomarkers at baseline and after 8 weeks of intervention.
One hundred adults were administered either 1,000 mg of rice bran extract or a placebo each day for 8 weeks.
Study Type
Interventional
Enrollment (Actual)
100
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Sang Yeoup Lee, MD, PhD
- Phone Number: 055 360-2860
- Email: saylee@pnu.edu
Study Contact Backup
- Name: Ye Li Lee
- Phone Number: 055 360-2860
- Email: yeri1230@gmail.com
Study Locations
-
-
Gyeungsangnam-do
-
Yangsan, Gyeungsangnam-do, Korea, Republic of, 50612
- Pusan National University Yangsan Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- the Korean version of the Hamilton Depression Rating Scale score between 7-24
Exclusion Criteria:
- No depressive symptom (K-HRSD ≤ 6) or severely depressed (K-HRSD ≥ 25)
- Those are taking hormone therapy such as estrogen within the past 6 months
- Those are taking the following drugs within the last 1 month or need to take them during the study period (sleep aids, antidepressants, selective estrogen receptor modulators, etc.)
- Those with a history of treatment for depression
- Abnormal liver or renal function (more than twice the normal upper limit of the research institute)
- Uncontrolled diabetes mellitus (>160 mg/dL of fasting blood sugar)
- Uncontrolled hypertension (>160/100 mmHg)
- Uncontrolled thyroid diseases.
- Those who are taking drugs, functional foods, herbs, etc. that may affect depression
- Alcohol abuser
- Allergic reaction to this test food
- Those who participated in other drug clinical trials within 1 month from the screening date.
- Severe gastrointestinal symptoms such as heartburn and indigestion
- Those who are pregnant, lactating, or plan to become pregnant during the clinical trial
- Those who are judged to be unsuitable by the PI for other reasons
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Rice bran extract group
This group takes rice bran extract for 8 weeks.
|
Rice bran extract 1,000 mg/day for 8 weeks
|
Placebo Comparator: Control group
This group takes a placebo for 8 weeks.
|
Placebo 1,000 mg/day for 8 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Korean version of the Hamilton Depression Rating Scale (K-HDRS)
Time Frame: 8 weeks
|
using K-HDRS score.
The minimum score was 0 and the maximum score was 50, and higher scores mean a worse outcome.
|
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Korean Version of the Beck-II Depression Inventory (K-BDI II)
Time Frame: 8 weeks
|
using K-BDI II score.
The minimum score was 0 and the maximum score was 63, and higher scores mean a worse outcome.
|
8 weeks
|
The Korean version of the Patient Health Questionnaire-9 (K-PHQ-9)
Time Frame: 8 weeks
|
using K-PHQ-9 score.
The minimum score was 0 and the maximum score was 27, and higher scores mean a worse outcome.
|
8 weeks
|
The Korean version of the Beck Anxiety Inventory (K-BAI)
Time Frame: 8 weeks
|
using K-BAI score.
The minimum score was 0 and the maximum score was 63, and higher scores mean a worse outcome.
|
8 weeks
|
The Korean of the Perceived Stress Scale(K-PSS)
Time Frame: 8 weeks
|
using K-PSS score.
The minimum score was 0 and the maximum score was 40, and higher scores mean a worse outcome.
|
8 weeks
|
serotonin concentration (nM)
Time Frame: 8 weeks
|
Change during 8 weeks
|
8 weeks
|
Brain-derived neurotrophic factor concentration (ng/ml)
Time Frame: 8 weeks
|
Change during 8 weeks
|
8 weeks
|
salivary cortisol concentration (U/mL)
Time Frame: 8 weeks
|
Change during 8 weeks
|
8 weeks
|
dopamine concentration (pg/μL)
Time Frame: 8 weeks
|
Change during 8 weeks
|
8 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Sang Yeoup Lee, MD, PhD, Pusan National University Yangsan Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 20, 2022
Primary Completion (Actual)
December 30, 2022
Study Completion (Actual)
December 31, 2022
Study Registration Dates
First Submitted
December 17, 2021
First Submitted That Met QC Criteria
December 17, 2021
First Posted (Actual)
January 6, 2022
Study Record Updates
Last Update Posted (Estimated)
February 2, 2024
Last Update Submitted That Met QC Criteria
January 31, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 02-2021-031
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
ProgenaBiomeRecruitingDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Vituity PsychiatryRecruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
University GhentUniversiteit Antwerpen; Janssen-Cilag Ltd.RecruitingDepression Moderate | Depression Severe | Depression MildBelgium
-
University of California, San FranciscoRecruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
Baylor College of MedicineUniversity of TexasRecruitingDepression | Depression Moderate | Depression Severe | Suicide and Self-harm | Depression in Adolescence | Depression MildUnited States
-
University of Cape TownNational Institute of Mental Health (NIMH)CompletedPostpartum Depression | Clinical Depression | Moderate DepressionSouth Africa
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; National Institute of Mental...CompletedMajor Depressive Disorder | Treatment Resistant Depression | Treatment-Refractory Depression | Late Life Depression | Geriatric DepressionUnited States, Canada
-
Northern Illinois UniversityUniversity Autonoma de Santo DomingoTerminatedDepression Moderate | Depression MildUnited States, Dominican Republic
-
Gerbera Therapeutics, Inc.Not yet recruitingPostpartum Depression | Depression, Postpartum | Postnatal Depression | Post-partum Depression | Post-Natal DepressionUnited States
Clinical Trials on Rice bran extract group
-
Chonbuk National University HospitalRecruitingImmunityKorea, Republic of
-
Qazvin University Of Medical SciencesUnknownHyperlipidemiasIran, Islamic Republic of
-
Poudre Valley Health SystemColorado State UniversityCompletedHyperlipidemiasUnited States
-
University of MiamiDaiwa Health DevelopmentCompletedHuman Immunodeficiency Virus InfectionUnited States
-
University of Southern CaliforniaCompletedInflammation in HIV InfectionUnited States
-
Colorado State UniversityThrasher Research Fund; Savica, Indonesia; Institute of Research for Development...Active, not recruitingSevere Acute MalnutritionIndonesia
-
Universidade Federal do Rio de JaneiroCompletedDietary ModificationBrazil
-
Fugeia NVCompletedHealthy Subjects | Gastrointestinal HealthBelgium
-
Unilever R&DLambda Therapeutic Research Ltd.Completed
-
Kellogg CompanyTufts University; University of Toronto; University of Saskatchewan; University... and other collaboratorsCompleted